<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:6e53bb31-dfc7-4dba-a7c6-a209735d44df,g:3528f456-ce7a-403d-82db-c8dea4e2db18,d:63024b33612d48a79cf72589cd29419c--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kin-20210825</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib9b57951ab524021b27ba5d250ff8bf9_D20200916-20200916" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y180L2ZyYWc6MDdkNWE3ZmYzOTAyNDM0Mzk2NmE0OTUyYjlhOTdlZDcvdGFibGU6OGFlZGRlYjMzNjllNDMwNjk3YmU3YmNiZjk0OTA3YjcvdGFibGVyYW5nZTo4YWVkZGViMzM2OWU0MzA2OTdiZTdiY2JmOTQ5MDdiN18wLTEtMS0xLTA_51e72409-29e0-4961-9ddd-43585f138945">0001561743</ix:nonNumeric><ix:nonNumeric contextRef="ib9b57951ab524021b27ba5d250ff8bf9_D20200916-20200916" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y180L2ZyYWc6MDdkNWE3ZmYzOTAyNDM0Mzk2NmE0OTUyYjlhOTdlZDcvdGFibGU6OGFlZGRlYjMzNjllNDMwNjk3YmU3YmNiZjk0OTA3YjcvdGFibGVyYW5nZTo4YWVkZGViMzM2OWU0MzA2OTdiZTdiY2JmOTQ5MDdiN18xLTEtMS0xLTA_c394d7aa-203f-4ff8-a7b8-90e2ec352c2f">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kin-20210825.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9f495076cd564e5c864f0c985348323d_D20210825-20210825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-25</xbrli:startDate><xbrli:endDate>2021-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3413b443f69040d8b779c953343b8d83_D20210825-20210825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-25</xbrli:startDate><xbrli:endDate>2021-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e32b58dc034f5ea8de5eae99745a2a_D20210825-20210825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-25</xbrli:startDate><xbrli:endDate>2021-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b57951ab524021b27ba5d250ff8bf9_D20200916-20200916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-16</xbrli:startDate><xbrli:endDate>2020-09-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i63024b33612d48a79cf72589cd29419c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84MjY_484f4f65-a1d6-4733-ad86-db4937a1f8cf">8-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84Mjc_fc9657fc-6e63-4a12-86d9-75d823728588">August 25, 2021</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84Mjg_8b3c628e-4301-485e-8ffc-7adbc72679e0">KINDRED BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:32.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6MTMwNGZhZGJjMzI2NDIzY2E3N2Y4NmVkYzNhMjc2NTMvdGFibGVyYW5nZToxMzA0ZmFkYmMzMjY0MjNjYTc3Zjg2ZWRjM2EyNzY1M18wLTAtMS0xLTA_927bb168-c416-41ee-a564-a9798a8dade3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6MTMwNGZhZGJjMzI2NDIzY2E3N2Y4NmVkYzNhMjc2NTMvdGFibGVyYW5nZToxMzA0ZmFkYmMzMjY0MjNjYTc3Zjg2ZWRjM2EyNzY1M18wLTItMS0xLTA_40ebbf65-c029-48c1-ade3-a020d8415d35">001-36225</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6MTMwNGZhZGJjMzI2NDIzY2E3N2Y4NmVkYzNhMjc2NTMvdGFibGVyYW5nZToxMzA0ZmFkYmMzMjY0MjNjYTc3Zjg2ZWRjM2EyNzY1M18wLTQtMS0xLTA_965d3abc-c5a7-4380-b20a-99b1d11a2d45">46-1160142</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84MjI_614fb9d6-c2e2-4cb4-a14f-8dc00ff33a93">1555 Bayshore Highway</ix:nonNumeric>, <ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84Mjk_a91e6afe-7eab-4f83-b484-70b02286fb65">Suite 200</ix:nonNumeric>, <ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84MzA_5f9dbdb0-cb8b-4b36-ae31-06bf464af870">Burlingame</ix:nonNumeric>, <ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84MjM_777d4a75-e3b6-4ba4-844f-63598cf9bbaf">California</ix:nonNumeric> <ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84MjQ_09e8cd13-f1b7-43d8-85e0-52bbd7d5035c">94010</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84MjU_daa605ff-bc34-4757-a6f1-f53131052f16">650</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGV4dHJlZ2lvbjpjYzY3OWExYTBkZDc0Zjc3YTE2M2U5YmQzZGJhMWE4Nl84MzE_30350dd4-5c59-4b7e-9f1a-33d2c43181a5">701-7901</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:3.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6OGRkNjhhYmM4MzI3NDBhOGEwMTFhZDQwMjVhMGQwZmUvdGFibGVyYW5nZTo4ZGQ2OGFiYzgzMjc0MGE4YTAxMWFkNDAyNWEwZDBmZV8wLTAtMS0xLTA_1bc87477-1c60-4e43-8f4f-dee7d23fcdb8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6OGRkNjhhYmM4MzI3NDBhOGEwMTFhZDQwMjVhMGQwZmUvdGFibGVyYW5nZTo4ZGQ2OGFiYzgzMjc0MGE4YTAxMWFkNDAyNWEwZDBmZV8xLTAtMS0xLTA_9419f82e-19a5-40b9-ac76-59c5caab6c41">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6OGRkNjhhYmM4MzI3NDBhOGEwMTFhZDQwMjVhMGQwZmUvdGFibGVyYW5nZTo4ZGQ2OGFiYzgzMjc0MGE4YTAxMWFkNDAyNWEwZDBmZV8yLTAtMS0xLTA_bddd15b3-37fa-4c4a-ab01-9a003ddd0864">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6OGRkNjhhYmM4MzI3NDBhOGEwMTFhZDQwMjVhMGQwZmUvdGFibGVyYW5nZTo4ZGQ2OGFiYzgzMjc0MGE4YTAxMWFkNDAyNWEwZDBmZV8zLTAtMS0xLTA_f0cdf18d-5e16-4be4-b01d-883ddc0026d9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:37.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3413b443f69040d8b779c953343b8d83_D20210825-20210825" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6ODY5YzljNzQ4Y2U4NGQ4YzliMjMwZWUwYTRjM2QyZGEvdGFibGVyYW5nZTo4NjljOWM3NDhjZTg0ZDhjOWIyMzBlZTBhNGMzZDJkYV8xLTAtMS0xLTA_a2713f43-add6-4846-a163-3fcb8f0efe7d">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3413b443f69040d8b779c953343b8d83_D20210825-20210825" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6ODY5YzljNzQ4Y2U4NGQ4YzliMjMwZWUwYTRjM2QyZGEvdGFibGVyYW5nZTo4NjljOWM3NDhjZTg0ZDhjOWIyMzBlZTBhNGMzZDJkYV8xLTItMS0xLTA_9b097a77-2ffa-42e0-89be-e35117fee15f">KIN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3413b443f69040d8b779c953343b8d83_D20210825-20210825" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6ODY5YzljNzQ4Y2U4NGQ4YzliMjMwZWUwYTRjM2QyZGEvdGFibGVyYW5nZTo4NjljOWM3NDhjZTg0ZDhjOWIyMzBlZTBhNGMzZDJkYV8xLTQtMS0xLTA_56f76d65-9962-415c-8753-d2a6de292ebc">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7e32b58dc034f5ea8de5eae99745a2a_D20210825-20210825" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6ODY5YzljNzQ4Y2U4NGQ4YzliMjMwZWUwYTRjM2QyZGEvdGFibGVyYW5nZTo4NjljOWM3NDhjZTg0ZDhjOWIyMzBlZTBhNGMzZDJkYV8yLTAtMS0xLTA_e17c47f9-7d4c-4835-b687-0a1e5dd15294">Preferred Stock Purchase Rights</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7e32b58dc034f5ea8de5eae99745a2a_D20210825-20210825" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6ODY5YzljNzQ4Y2U4NGQ4YzliMjMwZWUwYTRjM2QyZGEvdGFibGVyYW5nZTo4NjljOWM3NDhjZTg0ZDhjOWIyMzBlZTBhNGMzZDJkYV8yLTItMS0xLTA_101be54e-9769-4ee9-9a05-08097698e8c3">KIN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7e32b58dc034f5ea8de5eae99745a2a_D20210825-20210825" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6ODY5YzljNzQ4Y2U4NGQ4YzliMjMwZWUwYTRjM2QyZGEvdGFibGVyYW5nZTo4NjljOWM3NDhjZTg0ZDhjOWIyMzBlZTBhNGMzZDJkYV8yLTQtMS0xLTA_6f054d6d-4f8d-47fa-a4a8-4ec74600bdef">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f495076cd564e5c864f0c985348323d_D20210825-20210825" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjYzMDI0YjMzNjEyZDQ4YTc5Y2Y3MjU4OWNkMjk0MTljL3NlYzo2MzAyNGIzMzYxMmQ0OGE3OWNmNzI1ODljZDI5NDE5Y18xL2ZyYWc6Y2M2NzlhMWEwZGQ3NGY3N2ExNjNlOWJkM2RiYTFhODYvdGFibGU6ZDZiY2VmMmI5Njg4NGU2MWEwNDI3MDY2N2E4MTRjYTEvdGFibGVyYW5nZTpkNmJjZWYyYjk2ODg0ZTYxYTA0MjcwNjY3YTgxNGNhMV8xLTUtMS0xLTA_c03b8710-38d7-4034-aa7c-a322e176f4f8">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i63024b33612d48a79cf72589cd29419c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 5.07  Submission of Matters to a Vote of Security Holders.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On August 25, 2021, Kindred Biosciences, Inc., a Delaware corporation (&#8220;KindredBio&#8221;), held a special meeting of KindredBio&#8217;s stockholders at 8:00 a.m., Pacific Time at San Francisco Airport Marriott Waterfront Hotel, 1800 Old Bayshore Highway, Burlingame, California 94010 (the &#8220;KindredBio Special Meeting&#8221;). As of the close of business on July 20, 2021, KindredBio&#8217;s record date for the KindredBio Special Meeting, there were a total of 45,462,318 shares of common stock, par value $0.0001 per share, of KindredBio (&#8220;KindredBio common stock&#8221;), outstanding and entitled to vote at the KindredBio Special Meeting. At the KindredBio Special Meeting, 31,572,543 shares of KindredBio common stock were present or represented by proxy, and therefore, a quorum was present.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The results of the matters voted upon at the KindredBio Special Meeting, which are more fully described in KindredBio&#8217;s Definitive Proxy Statement on Schedule 14A as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on July 21, 2021 (the &#8220;Proxy Statement&#8221;) are set forth below. There were no broker non-votes with respect to any of the proposals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Proposal 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">: To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated June 15, 2021 (as it may be amended from time to time in accordance with its terms, including by the First Amendment, dated June 30, 2021, the &#8220;Merger Agreement&#8221;), by and among KindredBio, Elanco Animal Health Incorporated (&#8220;Elanco&#8221;) and Knight Merger Sub, Inc. (&#8220;Merger Sub&#8221;) (the &#8220;Merger Proposal&#8221;). Pursuant to, and subject to the terms and conditions of, the Merger Agreement, Merger Sub will merge with and into KindredBio (the &#8220;Merger&#8221;), with KindredBio surviving the Merger and becoming a wholly owned subsidiary of Elanco. The votes regarding the Merger Proposal were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">For</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Against</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Abstain</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">31,139,211</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">354,158</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">79,174</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Proposal 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">: To consider and vote on the proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable by KindredBio to its named executive officers that is based on or otherwise relates to the Merger (the &#8220;Merger-Related Compensation Proposal&#8221;). The votes regarding the Merger-Related Compensation Proposal were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">For</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Against</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Abstain</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">30,252,326</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,211,108</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">109,109</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As there were sufficient votes to approve the Merger Proposal, stockholder action on the proposal to approve any adjournment of the KindredBio Special Meeting to a later date or time, if necessary or appropriate, to solicit additional proxies in favor of the adoption of the Merger Agreement, as more fully described in the Proxy Statement, was not required, and KindredBio did not call a vote on the proposal.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.686%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KINDRED BIOSCIENCES, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   August 26, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Richard Chin         </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Richard Chin, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "kin-20210825.htm", "description": "8-K", "secsgml_size_bytes": 45221}]
{"company-data": {"conformed-name": "Kindred Biosciences, Inc.", "cik": "0001561743", "assigned-sic": "2834", "irs-number": "461160142", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36225", "film-number": "211209017"}, "business-address": {"street1": "1555 BAYSHORE HIGHWAY, SUITE 200", "city": "BURLINGAME", "state": "CA", "zip": "94010", "phone": "650-701-7901"}, "mail-address": {"street1": "1555 BAYSHORE HIGHWAY, SUITE 200", "city": "BURLINGAME", "state": "CA", "zip": "94010"}}
kin-20210825
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
August 25, 2021
KINDRED BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-36225
46-1160142
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
1555 Bayshore Highway
,
Suite 200
,
Burlingame
,
California
94010
(Address of principal executive offices) (Zip Code)
(
650
)
701-7901
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
KIN
The NASDAQ Stock Market LLC
Preferred Stock Purchase Rights
KIN
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.07  Submission of Matters to a Vote of Security Holders.
On August 25, 2021, Kindred Biosciences, Inc., a Delaware corporation ("KindredBio"), held a special meeting of KindredBio's stockholders at 8:00 a.m., Pacific Time at San Francisco Airport Marriott Waterfront Hotel, 1800 Old Bayshore Highway, Burlingame, California 94010 (the "KindredBio Special Meeting"). As of the close of business on July 20, 2021, KindredBio's record date for the KindredBio Special Meeting, there were a total of 45,462,318 shares of common stock, par value $0.0001 per share, of KindredBio ("KindredBio common stock"), outstanding and entitled to vote at the KindredBio Special Meeting. At the KindredBio Special Meeting, 31,572,543 shares of KindredBio common stock were present or represented by proxy, and therefore, a quorum was present.
The results of the matters voted upon at the KindredBio Special Meeting, which are more fully described in KindredBio's Definitive Proxy Statement on Schedule 14A as filed with the Securities and Exchange Commission ("SEC") on July 21, 2021 (the "Proxy Statement") are set forth below. There were no broker non-votes with respect to any of the proposals.
Proposal 1
: To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated June 15, 2021 (as it may be amended from time to time in accordance with its terms, including by the First Amendment, dated June 30, 2021, the "Merger Agreement"), by and among KindredBio, Elanco Animal Health Incorporated ("Elanco") and Knight Merger Sub, Inc. ("Merger Sub") (the "Merger Proposal"). Pursuant to, and subject to the terms and conditions of, the Merger Agreement, Merger Sub will merge with and into KindredBio (the "Merger"), with KindredBio surviving the Merger and becoming a wholly owned subsidiary of Elanco. The votes regarding the Merger Proposal were as follows:
For
Against
Abstain
31,139,211
354,158
79,174
Proposal 2
: To consider and vote on the proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable by KindredBio to its named executive officers that is based on or otherwise relates to the Merger (the "Merger-Related Compensation Proposal"). The votes regarding the Merger-Related Compensation Proposal were as follows:
For
Against
Abstain
30,252,326
1,211,108
109,109
As there were sufficient votes to approve the Merger Proposal, stockholder action on the proposal to approve any adjournment of the KindredBio Special Meeting to a later date or time, if necessary or appropriate, to solicit additional proxies in favor of the adoption of the Merger Agreement, as more fully described in the Proxy Statement, was not required, and KindredBio did not call a vote on the proposal.
Item 9.01
Financial Statements and Exhibits.
Exhibit No.
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KINDRED BIOSCIENCES, INC.
Date:   August 26, 2021
By:
/s/ Richard Chin
Richard Chin, M.D.
Chief Executive Officer